Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
NCT01257230
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. All patients and their parents (or legally accepted caregiver) must sign and date an informed consent consistent with ICH-GCP guidelines and local legislation prior to participation in the trial.
2. Male or female patients between 12 and 17 years of age.
3. All patients must have at least a 3 months history of asthma at the time of enrolment into the trial. The diagnosis of asthma has to be confirmed at visit 1 with a bronchodilator reversibility test.
4. All patients must have been on maintenance treatment with inhaled corticosteroids at a stable medium dose for at least 4 weeks before Visit 1.
5. All patients must be symptomatic (partly controlled) at Visit 1 (screening) and at randomisation defined by an Asthma Control Questionnaire (ACQ) mean score of more than or equal to 1.5.
6. All patients must have a pre-bronchodilator FEV1 more than or equal to 60% and less than or equal to 90% of predicted normal at Visit 1. Variation of absolute FEV1 values of Visit 1 as compared to Visit 2 must be within ± 30%.
7. All patients must have an increase in FEV1 of equal or above 12% and 200 mL after 400 µg salbutamol (albuterol) at Visit 1. If patients in the lower age range (e.g., 12 to 14 year olds) exhibit a very small total lung volume, positive reversibility testing might be based solely on the relative (12%) post-bronchodilator response.
8. All patients should be never-smokers or ex-smokers who stopped smoking at least one year prior to enrolment.
9. Patients should be able to use the Respimat® inhaler correctly.
10. Patients must be able to perform all trial related procedures including technically acceptable spirometric manoeuvres.
1. Patients with a significant disease other than asthma.
2. Patients with clinically relevant abnormal screening haematology or blood chemistry
3. Patients with a history of congenital or acquired heart disease, and/or have been
hospitalised for cardiac syncope or failure during the past year.
4. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
arrhythmia requiring intervention or a change in drug therapy within the past year.
5. Patients with malignancy for which the patient has undergone resection, radiation
therapy or chemotherapy within the last five years.
6. Patients with lung diseases other than asthma (e.g. Cystic Fibrosis). In case of
ex-premature infants, a history of significant bronchopulmonary dysplasia will be
regarded as exclusion criterion.
7. Patients with known active tuberculosis.
8. Patients with significant alcohol or drug abuse within the past two years.
9. Patients who have undergone thoracotomy with pulmonary resection.
10. Patients who are currently in a pulmonary rehabilitation program or have completed a
pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit
1).
11. Patients with known hypersensitivity to anticholinergic drugs, Benzalkonium chloride
(BAC), Ethylenediaminetetraacetic acis (EDTA) or any other components of the
tiotropium inhalation solution.
12. Pregnant or nursing adolescent female patients
13. Sexually active female patients of child-bearing potential not using a highly
effective method of birth control.
14. Patients who have taken an investigational drug within 4 weeks prior to Visit 1.
15. Patients who have been treated with long-acting anticholinergics (e.g. tiotropium
-Spiriva) within four weeks prior to screening (Visit 1).
16. Patients who are unable to comply with pulmonary medication restrictions prior to
randomisation.
17. Patients who have been treated with Anti-IgE treatment (Omalizumab Xolair) within the
last 6 months prior to screening.
18. Patients who have been treated with systemic (oral or intravenous) corticosteroids
within 4 weeks prior to screening (Visit 1).
19. Patients who have been treated with long-acting theophylline preparations within 2
weeks prior to screening (Visit 1) or during the run-in period
20. Patients who have been treated with other non-approved and according to international
guidelines not recommended ¿experimental¿ drugs for routine asthma therapy.
21. Patients with any acute asthma exacerbation or respiratory tract infection in the 4
weeks prior to Visit 1.
22. Patients requiring 10 or more puffs of rescue medication (salbutamol/albuterol) per
day on more than 2 consecutive days during the run-in period.
23. Patients who have previously been randomised in this trial or are currently
participating in another study.
24. Patients who are being treated with oral beta-blocker medication.
25. Patients with a known narrow-angle glaucoma, or any other disease where
anticholinergic treatment is contraindicated.
26. Patients with renal impairment, as defined by a creatinine clearance less than 50
mL/min/1.73 m2 Body Surface Area as calculated by Schwartz formula.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Denver, Colorado
- Columbia, Missouri
- Warrensburg, Missouri
- Boys Town, Nebraska
- Canton, Ohio
- Koblenz,
- Rosenheim,
- Wesel,
- Balvi,
- Daugavpils,
- Rezekne,
- Riga,
- Riga,
- Vilnius,
- Vilnius,
- Vilnius,
- Kamnik,
- Ljubljana,
- Maribor,
- Hallein,
- Linz,
- Neumarkt am Wallersee,
- Schlüsslberg,
- Thalheim bei Wels,
- Berlin,
- Berlin,
- Frankfurt,
- Hamburg,
- Hannover,
- Mainz,
- Schwerin,
- Wiesbaden,
- Wiesloch,
- Ivano-Frankivsk,
- Kharkiv,
- Kharkiv,
- Kiev,
- Kiev,
- Fountain Valley, California
- Fresno, California
- Stockton, California
- Waterbury, Connecticut
- Pensacola, Florida
- Chicago, Illinois
- Normal, Illinois
- Louisville, Kentucky
- New Orleans, Louisiana
- Omaha, Nebraska
- Ocean, New Jersey
- Albany, New York
- Great Neck, New York
- Rockville Centre, New York
- High Point, North Carolina
- Canton, Ohio
- Upland, Pennsylvania
- Richmond, Virginia
- Concord, New South Wales
- Mississauga, Ontario
- Ottawa, Ontario
- Montreal, Quebec
- Aalborg,
- Aarhus C,
- Berlin,
- Hamburg,
- Lübeck,
- Rüdersdorf,
- Weinheim,
- Bussolengo (vr),
- Milano,
- Pavia,
- Pietra Ligure (sv),
- Himeji, Hyogo,
- Hiroshima, Hiroshima,
- Itabashi-ku, Tokyo,
- Kagoshima, Kagoshima,
- Kishiwada, Osaka,
- Kitakyusyu, Fukuoka,
- Koga, Fukuoka,
- Kurashiki, Okayama,
- Kurume, Fukuoka,
- Morioka, Iwate,
- Osaka-sayama, Osaka,
- Sendai, Miyagi,
- Seto, Aichi,
- Urasoe, Okinawa,
- Urasoe, Okinawa,
- Wakayama, Wakayama,
- Groningen,
- Leeuwarden,
- Schiedam,
- Auckland NZ,
- Christchurch,
- Newtown Wellington NZ,
- Tauranga,
- St. Petersburg,
- St. Petersburg,
- St. Petersburg,
- Belgrade,
- Nis,
- Sremska Kamenica,
- Bellville,
- Cape Town,
- Cape Town,
- Cape Town,
- Ankara,
- Ankara,
- Izmit,
- Kharkov,
- Kiev,
- Vinnytsya,
- Chertsey,
- Exeter,
- Windsor,
- Linz,
- Schlüsslberg,
- Thalheim bei Wels,
- Wels,
- Brno,
- Kyjov,
- Kohtla-Järve,
- Tallinn,
- Großhansdorf,
- Hannover,
- Mannheim,
- Schwerin,
- Daugavpils,
- Riga,
- Riga,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma | |||
Official Title ICMJE | A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety Over 48 Weeks of Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler in Adolescents (12 to 17 Years Old) With Moderate Persistent Asthma. | |||
Brief Summary | The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma. Efficacy and safety will be assessed by measuring lung function parameters and evaluating the effects on asthma exacerbations, on Quality of life, on health care resource utilisation an on the number of adverse events. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
Condition ICMJE | Asthma | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 398 | |||
Original Estimated Enrollment ICMJE | 243 | |||
Actual Study Completion Date ICMJE | December 2013 | |||
Actual Primary Completion Date | December 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion criteria:
Exclusion criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 12 Years to 17 Years (Child) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Chile, Germany, Hungary, Italy, Korea, Republic of, Latvia, Mexico, Russian Federation, Slovakia, Spain, Ukraine, United States | |||
Removed Location Countries | Norway | |||
Administrative Information | ||||
NCT Number ICMJE | NCT01257230 | |||
Other Study ID Numbers ICMJE | 205.444 2010-021093-11 ( EudraCT Number: EudraCT ) | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Boehringer Ingelheim | |||
Study Sponsor ICMJE | Boehringer Ingelheim | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | Boehringer Ingelheim | |||
Verification Date | August 2014 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |